New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
19:16 EDTARNA, CRAY, Z, TRLA, NNA, PHMD, LOGM, VSI, GNC, GSK, LCAV, CLF, A, WTWOn The Fly: After Hours Movers
UP AFTER EARNINGS: Cliffs Natural (CLF), up 6.4% after reporting better-than-expected earnings and announcing it promoted Gary Halverson, formerly its president and COO, to president and CEO... LogMeln (LOGM), up 16%... Cray (CRAY), up 9.7%. ALSO HIGHER: LCA Vision (LCAV), up 29% after announcing an agreement to be acquired by PhotoMedex (PHMD) for $5.37 per share. Shares of PhotoMedex were little changed following the announcement... Arena Pharmaceuticals (ARNA), up 1.8% after the Daily Mail said GlaxoSmithKline (GSK) could be interested in a deal for the company. DOWN AFTER EARNINGS: Weight Watchers (WTW), down 20% after fourth quarter profit missed expectations and the company sharply cut its fiscal 2014 earnings outlook... GNC Holdings (GNC), down 15.7%... Trulia (TRLA), down 15.2%... Agilent (A), down 6%. ALSO LOWER: Vitamin Shoppe (VSI), down 8.5% after its vitamin retailing peer GNC reported disappointing fourth quarter sales and cut its fiscal 2014 outlook... Zillow (Z), down 3% after online real estate peer Trulia's quarterly report disappointed... Navios Maritime Acquisition (NNA), down 8.4% after filing to sell 12M shares of common stock.
News For WTW;GNC;TRLA;A;VSI;Z;CLF;LOGM;CRAY;LCAV;PHMD;ARNA;GSK;NNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
15:29 EDTPHMDPhotoMedex sells SLT surgical laser business to DaLian JiKang Medical Systems
Effective September 1, PhotoMedex and its subsidiary PhotoMedex Technology, entered into an Asset Purchase Agreement and a Supplemental Agreement with DaLian JiKang Medical Systems Import & Export Co., LTD. Under the Asset Purchase Agreement, JIKANG acquired the SLT surgical laser business from PTECH, for a total purchase price of $1.5M. The company will net approximately $1.2M after payment of closing and ancillary costs. The Purchase Price is payable to the company in three installments. An initial deposit of $300,000 was made on September 2. JIKANG will provide two letters of credit to the company for the remainder of the Purchase Price. The $1M Letter of Credit will become payable to the company on or about November 17, at which time substantially all the assets will be transferred to JIKANG in consummation of the transaction. The remaining Letter of Credit, for $200,000, will be payable to the company by February 17, 2016, after certain post-closing steps including the receipt of all assets at JIKANG's facilities and the training of JIKANG's personnel.
09:20 EDTGSKARIAD drawing interest from companies besides Baxalta, dealReporter says
Subscribe for More Information
September 3, 2015
16:47 EDTZZillow announces pending sale of Market Leader to Constellation Software
Zillow Group announced the pending sale of Market Leader to the Perseus Division of Constellation Software for $23M. The sale is expected to close early in the fourth quarter.
September 2, 2015
16:27 EDTLOGMLogMeln announces management succession plan
Subscribe for More Information
16:27 EDTAAgilent will will no longer include orders in financial reporting
Agilent Technologies announced it will no longer report orders in its periodic filings with the SEC or its quarterly earnings press releases, effective immediately. This change reflects feedback from several of the company's largest shareholders, and was also driven by the fact that Agilent was the only company among its peers to report orders. The other financial metrics included in the company's reporting provide comprehensive detail about Agilent's performance.
16:25 EDTLOGMLogMeln backs FY15 EPS view $1.51-$1.57, consensus $1.55
Subscribe for More Information
16:23 EDTLOGMLogMeln backs Q3 EPS 43c-44c, consensus 44c
Subscribe for More Information
12:46 EDTGSKGlaxoSmithKline reports 24.5% passive stake in Theravance Biopharma
Subscribe for More Information
September 1, 2015
07:34 EDTGSKAdaptimmune expands trial of T-cell therapy for synovial sarcoma
Adaptimmune Therapeutics (ADAP) announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients. Based on encouraging results in the first cohort of 10 patients, presented at the American Association for Cancer Research annual meeting in April 2015, the trial is being expanded to encompass an additional 20 patients in two further cohorts. The expansion of Adaptimmune's trial also triggers two milestone payments from GlaxoSmithKline (GSK). Adaptimmune is collaborating with GSK for the development of its NY-ESO TCR program through a strategic cancer immunotherapy partnership announced in June 2014. Under the terms of the agreement, GSK has an exclusive option to license Adaptimmune's NY-ESO TCR therapeutic and upon exercise would assume full responsibility for further development and commercialization of the therapeutic. Adaptimmune's clinical study includes synovial sarcoma patients who have received standard first line therapy containing ifosfamide and/or doxorubicin and who are intolerant or no longer responding to the regimen, and whose tumor expresses a tumor antigen known as NY-ESO-1. The NY-ESO-1 antigen is believed to be present in 60 to 70 percent of synovial sarcoma patients.The primary objectives of the study are to determine the safety of adoptively transferred autologous T cells expressing an affinity enhanced T cell receptor that recognizes the NY-ESO-1 antigen in HLA-A*0201, HLA-A*0205, and/or HLA-A*0206 positive patients with unresectable, metastatic or recurrent synovial sarcoma. Secondary objectives include the determination of efficacy through response rate and duration of response.
August 28, 2015
10:02 EDTLOGMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ADP (ADP) upgraded to Outperform from Market Perform at William Blair... ASML (ASML) upgraded to Buy from Hold at Berenberg... Abercrombie & Fitch (ANF) upgraded on Hollister fundamentals at RBC Capital... Akamai (AKAM) upgraded to Outperform from Market Perform at JMP Securities... Ares Capital (ARCC) upgraded to Outperform from Market Perform at Raymond James... Banco Santander (SAN) upgraded on valuation at Deutsche Bank... CIBC (CM) upgraded to Neutral from Underperform at Credit Suisse... Canon (CAJ) upgraded to Hold from Sell at Deutsche Bank... Citi (C) upgraded to Buy from Neutral at Guggenheim... Ctrip.com (CTRP) upgraded to Buy from Hold at Stifel... El Pollo Loco (LOCO) upgraded at Stifel... Genomic Health (GHDX) upgraded to Market Perform from Underperform at Raymond James... Golar LNG (GLNG) upgraded on valuation, upcoming project completion at Stifel... Habit Restaurants (HABT) upgraded to Buy from Hold at Stifel... Helmerich & Payne (HP) upgraded to Overweight from Equal Weight at Stephens... Himax (HIMX) upgraded to Outperform from Neutral at Credit Suisse... Huntington Bancshares (HBAN) upgraded to Buy from Neutral at Guggenheim... InterContinental (IHG) upgraded to Outperform from Neutral at Credit Suisse... Knight Transportation (KNX) upgraded to Strong Buy on valuation at Raymond James... LogMeln (LOGM) upgraded to Overweight from Sector Weight at Pacific Crest... Patterson Companies (PDCO) upgraded to Overweight from Neutral at Piper Jaffray... Qunar (QUNR) upgraded on valuation, positive catalysts at Stifel... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ryder (R) upgraded to Strong Buy from Outperform at Raymond James... SVB Financial (SIVB) upgraded to Buy from Neutral at DA Davidson... Seagate (STX) upgraded to Buy from Hold at Cross Research... Sinopec (SNP) upgraded to Neutral from Sell at Citi... Summit Hotel Properties (INN) upgraded to Outperform at Baird... Texas Capital (TCBI) upgraded to Buy from Neutral at DA Davidson... The Medicines Co. (MDCO) upgraded to Buy from Hold at Jefferies... U.S. Bancorp (USB) upgraded to Buy from Neutral at Guggenheim... Weatherford (WFT) upgraded to Overweight from Equal Weight at Stephens.
07:15 EDTLOGMLogMeln upgraded to Overweight on sustainable growth at Pacific Crest
Subscribe for More Information
06:56 EDTLOGMLogMeln upgraded to Overweight from Sector Weight at Pacific Crest
Subscribe for More Information
August 26, 2015
17:06 EDTGSKGilead AMBITION study results published in New England Journal of Medicine
Gilead Sciences (GILD) announced detailed results from the AMBITION study. In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50% compared to the pooled Letairis and tadalafil monotherapy arm. These data were published in The New England Journal of Medicine. Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union and other countries as once-daily treatments for patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is currently not approved.
11:01 EDTAAgilent partners with Weill Cornell Medical College for ALS research
Subscribe for More Information
08:22 EDTCRAYCray management to meet with Craig Hallum
Subscribe for More Information
August 24, 2015
13:15 EDTGSKFDA expands use of Novartis' Promacta to include children ages 1 and older
Ligand Pharmaceuticals (LGND) announced that the FDA has approved an expanded use for Promacta, a Novartis (NVS) product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was acquired by Novartis in March from GlaxoSmithKline (GSK). Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and was developed by GSK. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 years of age and older and in 2008 for use in adult patients with the same condition. The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among pediatric patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use